Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Stake Lifted by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD increased its stake in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 23.6% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 15,111 shares of the company’s stock after acquiring an additional 2,881 shares during the period. Price T Rowe Associates Inc. MD’s holdings in Kiniksa Pharmaceuticals were worth $299,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently modified their holdings of the company. KLP Kapitalforvaltning AS acquired a new stake in shares of Kiniksa Pharmaceuticals in the fourth quarter valued at $158,000. Tower Research Capital LLC TRC lifted its stake in Kiniksa Pharmaceuticals by 117.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,483 shares of the company’s stock worth $168,000 after acquiring an additional 4,575 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in Kiniksa Pharmaceuticals by 12.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company’s stock worth $174,000 after acquiring an additional 1,004 shares in the last quarter. Teacher Retirement System of Texas lifted its stake in Kiniksa Pharmaceuticals by 7.1% in the 4th quarter. Teacher Retirement System of Texas now owns 10,862 shares of the company’s stock worth $215,000 after acquiring an additional 719 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new position in Kiniksa Pharmaceuticals in the 4th quarter worth about $258,000. Institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals Stock Performance

NASDAQ:KNSA opened at $25.87 on Friday. The stock’s 50-day simple moving average is $22.77 and its 200 day simple moving average is $21.34. The company has a market cap of $1.89 billion, a P/E ratio of -184.77 and a beta of 0.07. Kiniksa Pharmaceuticals, Ltd. has a 52-week low of $17.38 and a 52-week high of $28.56.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, April 29th. The company reported $0.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.09. The business had revenue of $137.79 million for the quarter, compared to the consensus estimate of $128.35 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The firm’s quarterly revenue was up 72.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.25) earnings per share. As a group, equities analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current fiscal year.

Insider Activity at Kiniksa Pharmaceuticals

In other news, CEO Sanj K. Patel sold 2,872 shares of the business’s stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $27.03, for a total value of $77,630.16. Following the transaction, the chief executive officer now owns 96,674 shares in the company, valued at $2,613,098.22. The trade was a 2.89% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Ross Moat sold 64,035 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Tuesday, April 29th. The stock was sold at an average price of $25.21, for a total transaction of $1,614,322.35. Following the completion of the sale, the insider now directly owns 9,415 shares in the company, valued at $237,352.15. This trade represents a 87.18% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 231,640 shares of company stock valued at $5,669,136 in the last 90 days. 54.57% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Citigroup began coverage on Kiniksa Pharmaceuticals in a report on Thursday, March 13th. They set a “buy” rating and a $40.00 price objective on the stock. Jefferies Financial Group raised their price objective on Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the stock a “buy” rating in a research report on Tuesday, April 29th. Finally, Wedbush restated an “outperform” rating and set a $34.00 target price on shares of Kiniksa Pharmaceuticals in a research report on Wednesday, April 16th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Kiniksa Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $38.80.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.